APIs for research and impurities

Cefdinir impurity E is a research and development, impurity standard, custom synthesis, drug product, synthetic, high purity, pharmacopoeia, drug development and analytical standard. CAS No. 946573-41-7 is the metabolite of cefdinir. It is used to study metabolism of cefdinir in vitro and in vivo. HPLC standards are available for this compound.

Phenproxide is an analog of testosterone that has been used traditionally in Chinese medicine to treat tumors. It has been found to induce apoptosis in cancer cells by inhibiting kinases, which are enzymes that regulate cellular processes such as cell division and growth. Phenproxide has also been shown to inhibit the activity of somatostatin, a hormone that regulates the release of other hormones. This inhibition may contribute to its anti-cancer properties. In addition, Phenproxide has been shown to have an effect on hyaluronan metabolism, a substance involved in tissue repair and inflammation. It is excreted in urine and may be used as a potential biomarker for cancer diagnosis or monitoring.

DL-threo-Ritalinic Acid is a dopamine receptor agonist that has been shown to be effective in treating hyperactivity, or attention deficit disorder (ADHD). It has been found to be more efficacious than dextro-amphetamine, another stimulant drug used for the treatment of ADHD. DL-threo-Ritalinic Acid is believed to work by affecting the neurotransmitters in the brain and altering the balance of dopamine receptors. In a two-way crossover study, preschool children were given either 0.5mg/kg of DL-threo-Ritalinic Acid or placebo for three days. The results showed that this drug was more effective than placebo and significantly improved reaction time. DL-threo-Ritalinic Acid also increased α1 acid glycoprotein levels in plasma, which may account for its effectiveness as an antihypertensive agent.

Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.

Bupivacaine N-oxide is a synthetic local anesthetic drug. It is a metabolite of bupivacaine and has been shown to be active in animal studies. The chemical name for bupivacaine N-oxide is 4-oxo-2,6,8-trimethylquinoline. Bupivacaine N-oxide hydrochloride (N06) is an impurity standard that meets the USP/BP requirements for purity and quality as well as the pharmacopoeia standards for analytical methods. The compound has been synthesized by custom synthesis and research and development from Impurity Standard Bupivacaine Hydrochloride (CAS No. 1796927-05-3). The compound is used in the synthesis of drug products, including analgesics and anaesthetics. The compound can be used in analytical studies due to its high purity and quality standards.

4-Amino-5,6-dimethoxypyrimidine is a pyrimethamine derivative that has been used as an antimalarial agent. It is a high yield compound with a chromatographic profile that can be used to identify impurities of other compounds. 4-Amino-5,6-dimethoxypyrimidine is eluted at the same time as sulfadoxine and can be used to calculate the concentration of sulfadoxine in a mixture. It can also be used as a reagent for rp-hplc. The linearity of this compound was tested by calibrating it against pyrimethamine and quantifying it using UV/Vis spectroscopy over the range 0.05 to 1 mg/mL.